Study to Assess Safety and Efficacy of Atezolizumab (MPDL3280A) Compared to Best Supportive Care Following Chemotherapy in Patients With Lung Cancer [IMpower010]
3상
진행 중(모집 완료)
NCT02486718
| 대상 질환 | Non-Small Cell Lung Cancer |
|---|
| 임상 단계 | 3상 |
|---|
| 스폰서 | Hoffmann-La Roche |
|---|
| 상태 | 진행 중(모집 완료) |
|---|
| 참여자 수 | 1,280 명 |
|---|
| 중재(약물) | Atezolizumab, Cisplatin, Vinorelbine, Docetaxel, Gemcitabine |
|---|
| 시작일 | 2015년 10월 31일 |
|---|
| 완료일 | 2024년 1월 26일 |
|---|
| 결과 공개일 | 2025년 3월 30일 |
|---|
요약
This is a Phase III, global, multicenter, open-label, randomized study to compare the efficacy and safety of 16 cycles (1 cycle duration=21 days) of atezolizumab (MPDL3280A) treatment compared with best supportive care (BSC) in participants with Stage IB-Stage IIIA non-small cell lung cancer (NSCLC) following resection and adjuvant chemotherapy, as measured by disease-free survival (DFS) as assessed by the investigator and overall survival (OS). Participants, after completing up to 4 cycles of adjuvant cisplatin-based chemotherapy, will be randomized in a 1:1 ratio to receive atezolizumab for 16 cycles or BSC.
Disease-Free Survival (DFS) in Intent-to-treat (ITT) Population
Up to 95 months · months
| Atezolizumab | 65.6 months |
|---|
| Best Supportive Care (BSC) | 47.8 months |
|---|
| p-value | 0.0683 |
|---|
| Hazard Ratio (HR) | 0.848 (95% CI 0.710–1.013) |
|---|
DFS in All Randomized Stage II-IIIA Population
Up to 95 months · months
| Atezolizumab | 57.4 months |
|---|
| Best Supportive Care (BSC) | 40.8 months |
|---|
| Hazard Ratio (HR) | 0.830 (95% CI 0.691–0.998) |
|---|
DFS in the Programmed Death-ligand 1 (PD-L1) SP263 ≥ 1% Tumor Cell (TC) Subpopulation Within the Stage II-IIIA Population
Up to 95 months · months
| Atezolizumab | 68.5 months |
|---|
| Best Supportive Care (BSC) | 37.3 months |
|---|
| Hazard Ratio (HR) | 0.704 (95% CI 0.545–0.910) |
|---|
BENITIONS에서 보기
ClinicalTrials.gov 원문 보기
전체 임상
이 페이지는 ClinicalTrials.gov의 공개 데이터를 정리한 것입니다. 의학적 조언이 아니며 투자 권유나 자문도 아닙니다. 반드시 전문의와 상담하세요.